1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (CTKB) (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National ...
SINGAPORE] Flow cytometry company Cytek Biosciences has invested US$3 million in its Singapore facility as it expands its ...
FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. ...
FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year’s premier clinical industry events across the globe. Continuing ...
Operator: Thank you for standing by. My name is Luella, and I will be your conference operator today. At this time, I would like to welcome everyone to Cytek Biosciences’ Second Quarter 2024 Earnings ...
In the preceding three months, 4 analysts have released ratings for Cytek Biosciences (NASDAQ:CTKB), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...
“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...
Hosted on MSN
Cytek narrows 2025 revenue outlook to $196M-$205M amid recurring revenue growth and new product launches
CEO Wenbin Jiang reported that "second quarter revenue in 2025 was $45.6 million, down $1 million or 2.2% compared to the second quarter of 2024." He highlighted "lower product revenue in EMEA and ...
Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024 Expanded to a total installed base of 3,295 Cytek instruments, adding ...
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results